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ABSTRACT
Objectives: This study aimed to compare the serum IL-22 levels between preterm premature rupture of membranes 
(PPROM) patients and the control group with intact membranes. We also hypothesized whether serum IL-22 upregulation 
might contribute to defense against inflammatory responses and improve the pregnancy outcomes.
Material and methods: We performed this prospective case-control study between 24–34 weeks of pregnancy. We en-
rolled 40 singleton pregnant patients with PPROM and 40 healthy gestational age- and gravidity-matched patients without 
PPROM. The degree of association between variables and IL-22 were calculated by Spearman correlation coefficients where 
appropriate. Scatter plots were given for statistically significant correlations. ROC curve was constructed to illustrate the 
sensitivity and specificity performance characteristics of IL-22,  and a cutoff value was estimated by using the index of Youden.
Results: Maternal serum IL-22 levels were significantly higher in PPROM patients (60.34 ± 139.81 pg/mL) compared to the 
participants in the control group (20.71 ± 4.36 pg/mL, p < 0.001). When we analyze the area under the ROC curve (AUC), the 
IL-22 value can be considered a statistically significant parameter for diagnosing PPROM. According to the Youden index, 
a 23.86 pg/mL cut-off value of IL-22 can be used to diagnosing PPROM with 72% sensitivity and 61.5% specificity. There 
was no positive correlation between serum IL-22 levels and maternal C-reactive protein (CRP) value, procalcitonin value, 
latency period, birth week, birth weight, and umbilical cord blood pH value.
Conclusions: Maternal serum IL-22 levels were significantly higher in PPROM patients than healthy pregnant women with 
an intact membrane. We suggest that IL-22 might be a crucial biomarker of the inflammatory process in PPROM. 
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InTRODuCTIOn
Preterm premature rupture of membranes (PPROM) is 
described as rupture of the amniotic membranes before 
37 weeks of gestation [1]. This common obstetrical syndrome 
complicates approximately 3–4% of all pregnancies and is the 
identifiable leading cause of preterm birth, with about 40% of 
preterm deliveries being associated with PPROM [2]. PPROM 
is related to short-latency from membrane rupture to labor, 
infectious complications, and adverse neonatal outcomes 
associated with preterm birth [3]. These adverse outcomes 
include neonatal mortality and long-term complications of 
surviving neonates. Preterm labor is the single direct cause in 
35% of neonatal deaths. Surviving neonates often experience 
long-term consequences, including numerous physical ef-
fects (cardiovascular disease, chronic lung disease, hearing or 
visual impairment), behavioral deficiencies, and neurodevel-
opmental delay [4]. These complications represent a substan-
tial burden for the family, healthcare system, and society [5]. 
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Also, neonatal morbidity and mortality rates are higher in 
PPROM patients than the other subgroups of preterm deliver-
ies [6]. Therefore, it is crucial to determine the mechanisms 
implicated in PPROM and develop innovative treatments and 
strategies to prevent or manage this syndrome.   
During a healthy pregnancy, the maternal immune sys-
tem must prosecute in a delicate balancing act as maintain-
ing tolerance to the fetal allograft while preserving adaptive 
and innate immune mechanisms for protection against 
microbial infections [7, 8]. Infection and inflammation are 
implicated in the pathogenesis of PPROM. An imbalance in 
the production of anti-inflammatory and pro-inflammatory 
cytokines may activate different humoral and cellular im-
munologic components, amplifying the membrane weak-
ening and damage. PPROM is considered a disease of the 
fetal membranes. The inflammation-oxidative stress axis 
acts a significant role in producing pathways that can cause 
membrane weakening by several processes, including the 
activation of matrix-degrading proteases that lyse the col-
lagens and increasing the production of cytokines and pros-
taglandins [9]. Histological chorioamnionitis (HCA) being re-
ported in about 40–70% of PPROM patients [10]. Immediate 
and correct HCA diagnosis is essential; however, the event 
restricts that placental pathology can only be assessed after 
delivery [11]. The inflammatory response can also be shown 
in the amniotic fluid and maternal and fetal serum. Previous 
studies reported that HCA is associated with increased ma-
ternal and fetal serum levels of pro-inflammatory cytokines, 
including interleukin-1 beta (IL-1β), IL-2, IL-6, IL-8, IL-22, and 
tumor necrosis factor-alpha (TNF-α) [12].
IL-22 is a clinically relevant cytokine, mostly secreted by 
immune cells, including innate lymphoid cells (ILC), natural 
killer cells, T-helper 1 (Th1) cells, Th17 cells, Th22 cells, and 
lymphoid tissue inducer cells [13]. IL-22 is capable of mediat-
ing both pro-inflammatory and anti-inflammatory respons-
es, promotes epithelial cell proliferation and survival of epi-
thelial cells, wound repair, and induces the secretion of anti-
microbial proteins [14]. However, it remains unclear if IL-22 
upregulation might be associated with the pathological 
processes of the PPROM or it performs a different function. 
In a recent study, the authors suggested that IL-22 prevents 
preterm birth and promotes epithelial cell regeneration [15].
In this study, we aimed to compare the serum IL-22 lev-
els between PPROM patients and the control group with 
intact membranes. We also hypothesized whether serum 
IL-22 upregulation might contribute to defense against 
inflammatory responses and improve pregnancy outcomes.
MATERIAL AnD METHODS
We performed this prospective case-control study in Ka-
nuni Sultan Süleyman Training and Research Hospital Hospi-
tal from July 2019 to January 2020. This study was approved 
by the Ethics Committee of the same hospital. Informed 
consent forms were obtained from all participants. All the 
pregnant women were between the age of 18–40 years and 
240/7–340/7 weeks of gestation. Of the 80 pregnant women 
included in the study, we enrolled 40 singleton pregnant 
patients with PPROM as the study group and 40 healthy 
gestational age-, gravidity-, and body mass index (BMI)- 
-matched patients without PPROM as the control group. 
The control group consisted of patients who did not experi-
ence any complications associated with pregnancy in the 
later gestational weeks and had given birth at term.
Patients admitted to our hospital with the complaint or 
suspicion of PPROM were assessed in the emergency depart-
ment according to the ACOG criteria [16]. We diagnosed 
PPROM by using a sterile speculum to evaluate the amniotic 
fluid leakage from the cervix uteri and then examined uti-
lizing Amnisure®, a rapid test based on the Placental Alpha 
Microglobulin-1 (PAMG-1) detection in high concentrations 
in amniotic fluid [17]. The gestational week was determined 
by sonographic measurement and confirmed according to 
the last menstrual period and a first-trimester ultrasound 
exam. Patients with a confirmed PPROM diagnosis were 
hospitalized and referred to our obstetric department for 
further evaluation and proper treatment. We collected the 
blood samples to measure IL-22 levels at the time of the hos-
pitalization. We also took maternal blood samples to analyze 
complete blood count (CBC) every 72 hours, evaluating clini-
cal chorioamnionitis every eight hours after hospitalization 
and during the latency period [11]. All pregnant women with 
PPROM underwent ampicillin treatment daily to prevent 
chorioamnionitis and four doses of 6 mg of betamethasone 
for fetal lung maturation. We used Nifedipine to delay the 
preterm birth during the first 48 hours in all patients. 
The pregnancy termination was performed at the end of 
the 34th gestational weeks or early signs of clinical chorioam-
nionitis. Clinical chorioamnionitis was diagnosed with the 
following signs: fever (≥ 38ºC orally), maternal tachycardia 
(> 100 beats/minute), fetal tachycardia (> 160 beats/min-
ute), leukocytosis, purulent vaginal discharge, uterine 
tenderness, and abdominal pain [18]. We performed labor 
induction by cervical ripening with a vaginal prostaglandin 
E2 slow-release system [19]. Indication for cesarean section 
for non-reassuring fetal status was based on abnormal fetal 
heart rate monitoring [20].
We excluded patients with gestational hypertensive 
disorders, hepatic disease, multiple pregnancies, anemia, in-
fections, a history of ruptured amniotic membranes in their 
previous pregnancies, and co-existing morbidities, including 
diabetes mellitus, hypothyroidism, chronic hypertension, 
collagen vascular disease, renal disease, known malignancy, 
and ischemic heart disease. Patients with unavailable or 
incomplete medical records were also excluded.
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Maternal age, gravidity, parity, BMI, previous history of 
cesarean section, maternal serum hemoglobin value, white 
blood cell count (WBC), platelet value, mean corpuscular 
volume (MCV), red cell distribution width (RDW), C-reactive 
protein (CRP) value, procalcitonin value, IL-22 value, latency 
from membrane rupture to labor, and type of delivery (vagi-
nal or cesarean) were recorded. The birth week, birth weight, 
umbilical cord blood pH, 1- and 5-minute Apgar scores of 
the newborn were also recorded.
Serum IL-22 concentration was measured using an en-
zyme immunoassay (Catalog Number: EK0933, Boster Bi-
ological Technology 3942 Valley Ave Pleasanton, CA 
94566, USA) with a minimum detectable concentration of 
15.6 pg/mL and intra- and inter-assay coefficients of varia-
tion less than 5.1% and 6.3%, respectively. Absorbance at 
450 nm was measured using an SMR 16.1 Smart Microplate 
Reader (USCN KIT INC.).  
Statistical evaluation
We used the Kolmogorov-Smirnov and Shapiro Wilk 
tests to examine whether the data are normally distributed. 
We tested the homogeneities of variances by the Levene 
test. The Chi-square and/or Fisher’s exact tests for categorical 
variables and Student’s t-test or Mann-Whitney U test for 
continuous variables were used to evaluating differences 
between groups. The degree of association between vari-
ables and IL-22 were calculated by Spearman correlation 
coefficients where appropriate. Scatter plots were given 
for statistically significant correlations. Receiver operating 
characteristic (ROC) curve was constructed to illustrate the 
sensitivity and specificity performance characteristics of 
IL-22,  and a cutoff value was estimated by using the index 
of Youden. Frequencies (percentages), mean±standard de-
viation, and median (minimum-maximum) were given as 
descriptive statistics. We performed statistical analyses using 
IBM SPSS 20.0 for Windows (SPSS Inc., Chicago, IL, USA), and 
the p-value < 0.05 was considered statistically significant.  
RESuLTS
During the study period, 89 patients were enrolled in 
the study, of which 45 were PPROM patients. After with-
holding patients with missing medical records and applying 
the exclusion criteria, 40 patients remained in both groups.
We presented the demographic variables, clinical char-
acteristics, and the perinatal outcomes of the patients in 
Table 1. There were no significant differences between the 
two groups in terms of maternal age, gravidity, parity, BMI, 
history of a previous cesarean section, and delivery type.
Maternal serum IL-22 concentrations were significant-
ly higher in patients with PPROM (60.34 ± 139.81 pg/mL) 
Table 1. Comparison of demographic variables, clinical characteristics, and perinatal outcomes between control group and preterm premature 
rupture of membranes group 
Control group PPROM group p value
Age [years] 28.17 ± 5.27 27.69 ± 5.93 0.702
Gravidity 2.92 ± 1.32 2.82 ± 1.68 0.483
Parity 1.56 ± 1.18 1.28 ± 1.39 0.143
BMI [kg/m2] 27.51 ± 3.79 27.51 ± 4.86 0.997
Previous cesarean section, n (%) 19 (47.5) 14 (35.0) 0.252
IL-22 [pg/mL] 20.71 ± 4.36 60.34 ± 139.81 < 0.001
CRP [mg/L] 9.24 ± 0.49 11.30 ± 12.40 0.116
Procalcitonin [ng/mL] 0.03 ± 0.00 0.04 ± 0.02 < 0.001
WBC [/mm3 × 103] 11.21 ± 3.28 12.48 ± 3.71 0.653
Hemoglobin [g/dL] 11.48 ± 0.55 11.89 ± 1.33 0.116
Platelet [/mm3 ×103] 191.82 ± 6.62 272.07 ± 77.08 < 0.001
MCV [fL] 87.61 ± 1.06 84.12 ± 6.53 < 0.001
RDW [%] 13.46 ± 0.48 13.51 ± 2.08 0.289
Latency period [days] N/A 19.05 ± 18.00 N/A
Cesarean birth, n (%) 22 (55.0%) 26 (65.0%) 0.352
Birth week 39.15 ± 0.77 29.92 ± 4.11 < 0.001
Birth weight [g] 3662.56 ± 176.24 1746.53 ± 596.71 < 0.001
Umbilical cord  blood pH value 7.34 ± 0.04 7.30 ± 0.08 0.007
1-min Apgar 7.66 ± 0.66 4.74 ± 2.42 < 0.001
5-min Apgar 9.41 ± 0.49 7.10 ± 2.45 < 0.001
PPROM — preterm premature rupture of membranes; BMI — body mass index; CRP — C-reactive protein; WBC — white blood cell count; MCV — mean corpuscular 
volume; RDW — red cell distribution width; N/A — not available
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compared to the participants in the control group 
(20.71 ± 4.36 pg/mL, p < 0.001). When we analyze the area 
under the ROC curve (AUC), the IL-22 value can be considered 
a statistically significant parameter for diagnosing PPROM 
(Tab. 2, Fig. 1). According to the Youden index, a 23.86 pg/mL 
cut-off value of IL-22 can be used to diagnose PPROM with 
72% sensitivity and 61.5% specificity. 
There was no positive correlation between serum 
IL-22 levels and maternal CRP value, procalcitonin value, 
latency period, birth week, birth weight, and umbilical cord 
blood pH value (Tab. 3).
DISCuSSIOn
In the current study, we evaluated the concentrations 
of IL-22 in the maternal serum of the patients in association 
with the presence or absence of PPROM. Our study indicates 
that IL-22 demonstrated significantly increased levels in 
the serum of patients suffering from PPROM than control 
patients with intact membranes. However, we found no sig-
nificant correlation between the upregulation of maternal 
serum IL-22 levels and pregnancy outcomes.
Inflammation and oxidative stress are keenly associated 
with the pathogenesis of PPROM. These events are inducted 
in response to etiological factors with histochemical and 
biochemical results that may weaken the fetal membranes 
[9]. The immune mechanisms that play a role in these events 
may be local or systemic, namely, systemic involvement 
of immune factors located in circulating blood or local in-
volvement of elements in the fetomaternal unit’s layers 
[4, 21–23]. The amniotic fluid includes inflammatory cy-
tokines and molecules that can be utilized as biochemical 
markers to predict PPROM, including IL-1, IL-6, IL-22, and 
TNF-α [4]. However, amniocentesis is an invasive method 
with concomitant jeopardies. Also, oligohydramnios due to 
membrane rupture frequently makes this procedure chal-
lenging to obtain the amniotic fluid [11]. Therefore, a less 
invasive and more straightforward procedure of examining 
these cytokines in maternal serum would be beneficial for 
the prediction of PPROM. Since PPROM is described as the 
disease of the fetal membranes, several placental factors 
and pro-inflammatory cytokines have been implicated in the 
PPROM pathogenesis. However, few studies investigate the 
role of maternal serum inflammatory markers for predicting 
PPROM in the literature. This prediction model is essential for 
the obstetric units that are not well-resourced in which there 
is no chance to perform invasive methods for investigating 
these markers in the amniotic fluid. 
IL-22, an IL-10 family member, is a glycoprotein and 
secreted by cells of the innate and adaptive immune sys-
tem [24]. The primary biological characteristics of IL-22 
are pro-regenerative and anti-apoptotic properties [25]. 
Table 2. The area under the curve of the IL-22
ROC St. error 95% Confidence Interval p
Lower upper
IL-22 0.698 0.062 0.577 0.819 < 0.001
ROC — Receiver operating characteristic
Table 3. Correlations between IL-22 value and other parameters
IL-22






r 0.008  –0.016 0.023
p 0.969 0.921 0.845
Procalsitonin [ng/mL]
r 0.021 0.266 0.158
p 0.897 0.102 0.167
Latency period [days]
r N/A –0.015 –0.015
p N/A 0.926 0.926
Birth week
r –0.116 –0.207 –0.129
p 0.482 0.205 0.261
Birth weight
r –0.067 –0.186 –0.107
p 0.684 0.257 0.352
Umbilical cord blood 
pH value
r –0.062 –0.303 –0.212
p 0.708 0.061 0.062
1-min Apgar
r –0.029 –0.264 –0.158
p 0.861 0.104 0.166
5-min Apgar
r 0.125 –0.165 –0.071
p 0.448 0.315 0.536













0.0                     0.2                     0.4                     0.6                     0.8                     1.0
1 - Specicity
Diagonal segments are produced be ties
Figure 1. Receiver operating characteristic (ROC) curve for serum 
IL-22 concentrations in patients with preterm premature rupture of 
membranes
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IL-22 has been demonstrated to modulate the secretion 
of numerous genes encoding proteins involved in tissue 
protection, differentiation, remodeling, and survival, and to 
a more secondary amount, pro-inflammatory proteins [26]. 
Previous studies reported that IL-22 plays a pivotal role in 
several immune-mediated inflammatory diseases such as 
inflammatory bowel diseases, rheumatoid arthritis, psoriasis, 
and allergic diseases [24]. 
IL-22 acts primarily in epithelial and stromal cells. 
In human pregnancy, trophoblast cells are epithelial cells 
that stemmed fetal origin and promote pregnancy main-
tenance. Wang et al. stated that IL-22 enhances cell viabil-
ity, promotes proliferation, and decreases the apoptosis of 
trophoblast cells. They suggested that IL-22 might be a use-
ful cytokine for the completion of gestation [27]. Dambaeva 
et al. [14], indicated that IL-22 is upregulated in response 
to lipopolysaccharide (LPS) injection into pregnant mice’s 
uterus and proposes the probable administration of IL-22 to 
control inflammation-induced preterm delivery [15]. They 
also stated that LPS-induced pregnancy loss and fetal death 
risk in IL-22 k/o mice were significantly reduced with recom-
binant IL-22 (rIL-22) injection. Moreover, rIL-22 injection 
inhibited LPS-triggered preterm delivery in an IL-22 +/+ 
mice. Xu et al. [28] suggested that ILCs are implicated in the 
localized inflammatory milieu that accompanies preterm 
birth pathogenesis by expressing a high level of IL-22. Our 
study showed that maternal serum IL-22 concentrations 
were higher in women with PPROM (60.34 ± 139.81 pg/mL) 
than in the control group (20.71 ± 4.36 pg/mL, p < 0.001). We 
think that this result conclusively demonstrated the inflam-
mation in the pathological process of PPROM.
We also assessed whether there is a relationship be-
tween maternal serum IL-22 concentration and latency 
period and neonatal outcomes, including birth week, birth 
weight, umbilical cord blood pH value, 1- and 5-minute 
Apgar scores. We found no correlation between maternal 
serum IL-22 levels and neonatal outcomes. Aris et al. [29] 
concluded that PPROM in the previous gestation is related 
to significant adverse neonatal outcomes in the subsequent 
gestation. We exclude all patients with a history of PPROM to 
eliminate this risk factor. Martinez-Portilla et al. and Sorokin 
et al. found no significant association between maternal 
serum inflammatory markers and adverse neonatal out-
comes [11, 30]. 
To the best of our knowledge, this is the first study to 
date that has assessed the serum IL-22 concentrations in 
PPROM patients and compared with healthy pregnant wom-
en with intact membranes. Also, we included the control 
and PPROM patient groups that were matched for maternal 
age, gestational age at blood sample collection, or BMI. 
As IL-22 levels may vary with these factors, we eliminate the 
ones that could introduce potential bias.
This study’s main limitation is the absence of confirming 
the inflammation by the histopathological examination after 
birth. Further studies are required in which the association 
between maternal serum IL-22 levels and clinical outcomes 
are confirmed by postnatal histopathological evaluation. 
COnCLuSIOnS
Maternal serum IL-22 levels were significantly higher in 
PPROM patients than healthy pregnant women with an in-
tact membrane. We suggest that IL-22 might be a crucial 
biomarker of the inflammatory process in PPROM. However, 
there was no positive correlation between serum IL-22 levels 
and maternal CRP value, procalcitonin value, latency period, 
birth week, birth weight, and umbilical cord blood pH value. 
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